Day: June 4, 2023

Reference is made to the notice on 24 May 2023 regarding completion a private placement of 147.1 million shares at NOK 0.85 per share in IDEX Biometrics ASA. The placement was split in two tranches of 116.9 million shares and 30.2 million shares respectively. The capital increase of 116,897,492 Tranche 1 shares has been registered and the shares will be issued soonest. The company’s share capital is now NOK 192,880,861.80 divided into 1,285,872,412 shares, each with a nominal value of NOK 0.15. The issue of 30,161,332 Tranche 2 shares will be considered and resolved by an extraordinary general meeting of shareholders on 16 June 2023. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX Biometrics (OSE: IDEX and Nasdaq: IDBA) is a leading...

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference call and webcast today at 6:00 p.m. CT BRISBANE, Calif., June 04, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib (DAY101). These data were shared in an oral presentation today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition, the Company announced that it has initiated...

– Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment – – Trilaciclib Enhances Expression of Genes Associated with Memory T Cells – – Trilaciclib Increases Multiple Surrogate Immune Markers for Memory CD8+ T Cell Differentiation, Infiltration, and Function – RESEARCH TRIANGLE PARK, N.C., June 04, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer (TNBC) prior to receiving trilaciclib and neoadjuvant therapy. These results highlight the potential for trilaciclib to enhance...